Avantor Results Presentation Deck

Summary Li Strong business momentum continued in Q4 Reported revenues, margin expansion and earnings growth Favorable end markets led by Biopharma ABS toolkit driving continued execution to offset inflation - Executing on our long-term growth strategy Continued focus on proprietary growth through Biopharma platform Investing in core capabilities to sustain long-term growth M&A contributing; closed Masterflex Looking ahead Growing core growth, modest COVID-19 headwinds Commitment to strong 2022 performance Remain focused on M&A integration and deleveraging avantor™ 11

View entire presentation